Amneal Takes A Step Forward On Biosimilars

FDA Accepts Filing For Bevacizumab Rival To Avastin, Partnered With Mabxience

The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.

Wooden blocks 2021, 2022, 2023
Amneal plans to build up its biosimilars business with a launch every year to 2023 • Source: Alamy

Amneal has moved closer to its goal of launching a US biosimilar every year from 2021 to 2023, after the US Food and Drug Administration accepted for filing the firm’s biologics license application for bevacizumab.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products